Qingmei Hong
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Regulation of Appetite and Obesity, Biochemical Analysis and Sensing Techniques, melanin and skin pigmentation, Chemical Synthesis and Reactions, Synthesis and pharmacology of benzodiazepine derivatives
Most-Cited Works
- → Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain(2014)41 cited
- → Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase(2013)36 cited
- → Preparations of Secondary Amines and .beta.-Amino Esters via Additions of Grignard and Reformatsky Reagents to Imines and by One-Pot Reactions of Primary Amines, Aldehydes, and Grignards(1995)29 cited
- → 1-(Trimethylsilyl)benzotriazole-Assisted Addition of Grignard Reagents to Imines: A Versatile Approach to Aliphatic Secondary Amines(1994)27 cited
- → Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety(2014)26 cited
- → Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist(2010)23 cited
- → Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes(2015)23 cited
- → Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity(2010)21 cited
- → The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes(2012)18 cited
- → Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands(2005)18 cited